Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 12;8(1):25.
doi: 10.1186/s41256-023-00311-4.

Prevalence and trends of polypharmacy in U.S. adults, 1999-2018

Xiaowen Wang  1   2 , Keyang Liu  3 , Kokoro Shirai  3 , Chengyao Tang  3 , Yonghua Hu  4   5 , Ying Wang  6 , Yuantao Hao  7   8 , Jia-Yi Dong  9
Affiliations

Prevalence and trends of polypharmacy in U.S. adults, 1999-2018

Xiaowen Wang et al. Glob Health Res Policy. .

Abstract

Background: Polypharmacy is one of the most important health issues for its potential impacts on disease burden and healthcare costs. The aim of this study was to update a comprehensive picture of prevalence and trends in polypharmacy over 20 years in U.S. adults.

Methods: Participants included 55,081 adults aged ≥ 20 from the National Health and Nutrition Examination Survey, January 1, 1999, through December 31, 2018. The simultaneously use of ≥ 5 drugs in one individual was defined as polypharmacy. National prevalence and trends in polypharmacy were evaluated among U.S. adults within different demo-socioeconomic status and pre-existing diseases.

Results: From 1999-2000 to 2017-2018, the overall percentages of adults with polypharmacy remained on the rise, increasing from 8.2% (7.2-9.2%) to 17.1% (15.7-18.5%) (average annual percentage change [AAPC] = 2.9%, P = .001). The polypharmacy prevalence was considerably higher in the elderly (from 23.5% to 44.1%), in adults with heart disease (from 40.6% to 61.7%), and in adults with diabetes (from 36.3% to 57.7%). Also, we observed a greater increase rate of polypharmacy in men (AAPC = 4.1%, P < .001), in the Mexican American (AAPC = 6.3%, P < .001), and in the non-Hispanic Black (AAPC = 4.4%, P < .001).

Conclusions: From 1999-2000 to 2017-2018, the prevalence of polypharmacy is continually increasing in U.S. adults. The polypharmacy was especially higher in the older, in patients with heart disease, or diabetes. The high prevalence urges the healthcare providers and health policymakers to manage polypharmacy among specific population groups.

Keywords: Medication; NHANES; National Health and Nutrition Examination Survey; Polypharmacy; Prevalence; Trends.

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest relevant to this article were reported.

Figures

Fig. 1
Fig. 1
Prevalence and trend of polypharmacy among U.S. adults (1999–2018)
Fig. 2
Fig. 2
Prevalence and trend of polypharmacy among U.S. adults, by sex (A), age group (B), and race (C) (1999–2018)
Fig. 3
Fig. 3
Prevalence and trend of polypharmacy among U.S. adults, by education (A), and by income (B) (1999–2018)
Fig. 4
Fig. 4
Prevalence and trend of polypharmacy among U.S. adults, by diagnosed disease (1999–2018)
See this image and copyright information in PMC

References

    1. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States From 1999–2012. JAMA. 2015;314:1818–1831. doi: 10.1001/jama.2015.13766. - DOI - PMC - PubMed
    1. Charlesworth CJ, Smit E, Lee DS, Alramadhan F, Odden MC. Polypharmacy among adults aged 65 years and older in the United States: 1988–2010. J Gerontol A Biol Sci Med Sci. 2015;70:989–995. doi: 10.1093/gerona/glv013. - DOI - PMC - PubMed
    1. Delara M, Murray L, Jafari B, Bahji A, Goodarzi Z, Kirkham J, Chowdhury Z, Seitz DP. Prevalence and factors associated with polypharmacy: a systematic review and Meta-analysis. BMC Geriatr. 2022;22:601. doi: 10.1186/s12877-022-03279-x. - DOI - PMC - PubMed
    1. Khezrian M, McNeil CJ, Murray AD, Myint PK. An overview of prevalence, determinants and health outcomes of polypharmacy. Ther Adv Drug Saf. 2020;11:2042098620933741. doi: 10.1177/2042098620933741. - DOI - PMC - PubMed
    1. Onder G, Marengoni A. Polypharmacy. JAMA. 2017;318:1728. doi: 10.1001/jama.2017.15764. - DOI - PubMed

Publication types

LinkOut - more resources